ClinicalTrials.gg
RecruitingNCT07105709Updated Feb 2, 2026

Open-label Extension Study in Participants With Early Alzheimer's Disease

A Phase 2 interventional study of GSK4527226 in Alzheimer's Disease, sponsored by GlaxoSmithKline. Recruiting at 33 sites in 11 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Not applicable
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 34 studies in Alzheimer Disease by GlaxoSmithKline — 2 open to participants now, 2 under way, none of them phase 3. Alzheimer Disease · GlaxoSmithKline.

Planned enrollment
14th of 34
220 · median 120
Started
2025
the only one that year
Phase 2
11 of 34
1 open now
Registered
33rd of 34
by date

Among the 34 studies in Alzheimer Disease by GlaxoSmithKline, this one is the 14th largest by planned enrollment, is the only one that started in 2025, is one of 11 in phase 2, and was the 33rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 34 studies in Alzheimer Disease by GlaxoSmithKline are open now, in 11 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Alzheimer Disease by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study medicine GSK4527226 is being studied in participants with Alzheimer's Disease (AD) in study 219867 (the parent study, NCT06079190). This new study is an extension of that parent study called an open-label extension (OLE). An OLE is a clinical trial where all participants receive the same study medicine. Participants must already be in study 219867 to be able to take part in this study. This study will assess the long-term safety and efficacy of GSK4527226 in participants with early AD (including mild cognitive impairment [MCI] and mild dementia due to AD) who have completed the parent study.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer's Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Mental Disorders
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the Treatment Period in the parent study (NCT06079190).
  • Participants may have missed doses during the Treatment Period or may be on a temporary dose suspension but must not have been permanently discontinued early from study intervention or withdrawn from the parent study.
  • Willing and able to give , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).
  • Availability of an adult person who has frequent and sufficient contact with the participant, is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the study partner ICF.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of follows requirements outlined in the protocol.
  • A male participant is eligible to participate if he follows contraception requirements outlined in the protocol.

Exclusion criteria

Exclusion Criteria:

  • corrected (QTc) assessment at Day 1 that meets the stopping criteria described in the protocol.
  • Participant is taking or will be starting a prohibited medication described in the protocol.
  • Evidence of any Amyloid related imaging abnormalities (ARIA) or cerebral macrohemorrhage that meets the permanent discontinuation criteria described in the protocol.
  • Other newly identified intracranial hemorrhage aneurysm, vascular malformation, infective lesion, space occupying lesion or brain tumor, or other Magnetic resonance imaging (MRI) findings contraindicating participation in the study.
  • Newly identified infection(s) that may affect the Central nervous system (CNS).
  • New diagnosis of moderate to severe alcohol and/or substance use disorder.
  • Change in participant's ability to tolerate MRI procedures, to MRI, or any other clinical history or examination finding that would pose a potential hazard in combination with MRI.
  • Newly diagnosed cancer.
  • Newly identified severe allergic, anaphylactic, or other reactions to chimeric, human, or humanized antibodies or fusion proteins.
  • Newly identified genetic predisposition for clotting disorder or hemorrhagic disease.
  • Any other change in health status (which, in the opinion of the investigator, would make the participant unsuitable for participation in the OLE study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    GSK4527226

    Participants will receive GSK4527226.

    Drug: GSK4527226

Interventions

  • DrugGSK4527226

    GSK4527226 will be administered.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) during the OLE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.

    Time frame: Up to 112 Weeks

  2. Number of Participants with Adverse Event of Special Interest (AESIs) during the OLE

    AESIs includes Infusion-related reactions, Amyloid related imaging abnormalities (ARIA) and cerebral macrohemorrhage.

    Time frame: Up to 112 Weeks

  3. Number of Participants with Serious Adverse Events (SAEs) during the OLE

    A SAE is defined as any untoward medical occurrence that, at any dose, results in death and is life threatening requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, or is a birth defect or congenital anomaly.

    Time frame: Up to 112 Weeks

  4. Number of Participants with Amyloid related imaging abnormalities (ARIAs) Including Severity during the OLE

    Magnetic resonance imaging (MRIs) will be used to monitor for abnormalities in the brain such as brain swelling and/or brain bleeding, which are termed as ARIAs.

    Time frame: Up to 112 Weeks

Secondary outcomes

  1. Change from OLE Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score Across Weeks 24, 52, 76, and 104

    The CDR-SB score is a quantitative general index that provides more precision in participants with mild dementia. The CDR scale is a clinician-rated dementia staging system tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5- point scale in which 0=None, 0.5=Questionable, 1= Mild, 2=Moderate, and 3=Severe. The CDR-SB score is obtained by adding the ratings in each of the 6 categories and total score ranges from 0 to 18 with higher scores indicative of greater impairment.

    Time frame: Baseline, Week 24, 52, 76, and 104

  2. Change from OLE Baseline in AD Assessment Scale-Cognitive subscale (ADAS-Cog14) Score Across Weeks 24, 52, 76, and 104

    The AD Assessment Scale-Cognitive subscale (ADAS-Cog14) is a 14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. The ADAS Cog-14 score ranges from 0 to 90 and higher scores indicate greater impairment.

    Time frame: Baseline, Week 24, 52, 76, and 104

  3. Change from OLE Baseline in Mini - Mental State Exam (MMSE) Across Weeks 24, 52, 76, and 104

    The MMSE is a brief test used to screen for cognitive impairment. It is routinely used for estimating the severity of cognitive impairment and tracking cognitive changes in an individual over time. The MMSE assesses orientation (time and place), registration, attention and calculation, recent memory, language (naming, comprehension, and repetition), and constructional praxis (copying a figure). The MMSE score ranges from 0 to 30, with higher scores indicating better cognitive performance.

    Time frame: Baseline, Week 24, 52, 76, and 104

  4. Change from OLE Baseline in ADCS-ADL-MCI Score Across Weeks 24, 52, 76, and 104

    The AD Cooperative Study - Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-ADL-MCI). The ADCS-ADL for MCI is a 23-item scale that measures the competence of participants in basic and instrumental activities of daily living. Total scores on the ADCS-ADL-MCI range from 0 to 53 where lower scores indicates greater functional impairment.

    Time frame: Baseline, Week 24, 52, 76, and 104

  5. Change from OLE Baseline in Integrated Alzheimers Disease Rating Scale (iADRS) Score Across Weeks 24, 52, 76, and 104

    The iADRS is a composite tool that measures both cognition and function. The iADRS combines scores from the ADAS-Cog-14 and the Alzheimer's Disease Cooperative Study-instrumental Activities of Daily Living (ADCS-iADL). The ADAS-Cog-14 is a 14-item version of the test that assesses immediate and delayed memory, confrontational naming, ability to follow commands, ideational and constructional praxis, orientation, language, and attention. The ADCS-iADL is a 23-item scale measuring basic and instrumental abilities in participants with mild to moderate AD. The iADRS score is then computed as the sum of the transformed ADAS-Cog14 and the ADCS-iADL with scores ranging from 0 to 144 and lower scores indicating worse performance.

    Time frame: Baseline, Week 24, 52, 76, and 104

  6. Change from OLE Baseline in Alzheimers Disease Composite Score (ADCOMS) Across Weeks 24, 52, 76 and 104

    The ADCOMS is a composite score comprising scores from the MMSE, ADAS-Cog14, and CDR-SB. It contains a total of 12 cognitive and functional items, including 4 items from the ADAS-Cog14, 2 items from the MMSE, and 6 items from the CDR-SB. The ADCOMS scores range from 0 to 1.97, with a higher score indicative of greater impairment.

    Time frame: Baseline, Week 24, 52, 76 and 104

07

Study locations

33 of 33 sites recruiting
  • GSK Investigational Site
    Maitland, Florida 32752, United States
    Recruiting
  • GSK Investigational Site
    Miami, Florida 33176, United States
    Recruiting
  • GSK Investigational Site
    Stuart, Florida 34997, United States
    Recruiting
  • GSK Investigational Site
    Toms River, New Jersey 08755, United States
    Recruiting
  • GSK Investigational Site
    Staten Island, New York 10314, United States
    Recruiting
  • GSK Investigational Site
    Matthews, North Carolina 28105, United States
    Recruiting
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • GSK Investigational Site
    Houston, Texas 77030, United States
    Recruiting
  • GSK Investigational Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • GSK Investigational Site
    Buenos Aires, 1897, Argentina
    Recruiting
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aire, C1431FWO, Argentina
    Recruiting
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABJ, Argentina
    Recruiting
  • GSK Investigational Site
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
    Recruiting
  • GSK Investigational Site
    Ottawa, Ontario K1Z 1G3, Canada
    Recruiting
  • GSK Investigational Site
    Peterborough, Ontario K9H 2P4, Canada
    Recruiting
  • GSK Investigational Site
    Toronto, Ontario M3B 2S7, Canada
    Recruiting
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2J2, Canada
    Recruiting
  • GSK Investigational Site
    Sherbrooke, Quebec J1J 2G2, Canada
    Recruiting
  • GSK Investigational Site
    Oulu, 90100, Finland
    Recruiting
  • GSK Investigational Site
    Bergen, 5009, Norway
    Recruiting
  • GSK Investigational Site
    Oslo, 0450, Norway
    Recruiting
  • GSK Investigational Site
    Junggu, 400711, South Korea
    Recruiting
  • GSK Investigational Site
    Barcelona, 08028, Spain
    Recruiting
  • GSK Investigational Site
    Gothenburg, 431 41, Sweden
    Recruiting
  • GSK Investigational Site
    Malmö, 21146, Sweden
    Recruiting
  • GSK Investigational Site
    Stockholm, Sweden
    Recruiting
  • GSK Investigational Site
    Tainan, 704, Taiwan
    Recruiting
  • GSK Investigational Site
    Taoyuan, 333, Taiwan
    Recruiting
  • GSK Investigational Site
    Birmingham, B16 8LT, United Kingdom
    Recruiting
  • GSK Investigational Site
    Bristol, BS32 4SY, United Kingdom
    Recruiting
  • GSK Investigational Site
    London, W1G 8TA, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's planned 37 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2025
First posted
Aug 6, 2025
StartActual
Aug 14, 2025
Primary completionEst.
Sep 15, 2028
CompletionEst.
Dec 8, 2028
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07105709
Lead sponsor
GlaxoSmithKline
Collaborators
Alector Inc.
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 14, 2025
Primary completion
Sep 15, 2028 (estimated)
Completion
Dec 8, 2028 (estimated)
Last update
Feb 2, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion